Dyslipidemia and Hypertension: Management Issues

The worldwide cardiovascular death rate and disease incidence is increasing for dyslipidemic hypertension, which denotes a condition with both abnormal lipids and high blood pressure.Research indicates that people with high blood pressure develop abnormal lipid profiles more frequently and vice versa, than the average population.The combination of these two conditions leads to faster atherosclerosis development, which produces cardiovascular risks that surpass the combined effects of each condition separately.Dyslipidemic hypertension leads to faster vascular damage because of endothelial dysfunction, oxidative stress, and lipid accumulation, which makes atherosclerosis progress faster.The implementation of managed care methods, which coordinate blood pressure and lipid level treatment, leads to substantial decreases in coronary artery disease, stroke, and cardiovascular death rates.The review examines how various antihypertensive drug classes influence lipid metabolism to show that patients with dyslipidemia need personalized treatment plans.It assesses newer pharmacological treatments together with obstacles faced in enhancing cardiovascular outcomes during extended medical care.